LEO To Focus on New Data for CHE, AD, and PsO at EADV 2025
Key Takeaways
LEO Pharma will present its largest portfolio to date at EADV 2025, including 5 late-breakers and 24 abstracts.
Some of the reseaerch includes new adolescent data for delgocitinib and phase 2b findings for temtokibart in atopic dermatitis (AD).
The presentations reflect a strategic focus on chronic, severe, and underserved dermatologic conditions, according to the company.
LEO Pharma has unveiled its largest-ever scientific program for presentation at the 2025 European Academy of Dermatology and Venereology (EADV) Congress, chronic hand eczema (CHE), atopic dermatitis (AD), and plaque psoriasis, along with updates on investigational agents and real-world data from several pivotal trials.
Among the headline presentations was new phase 2b data ontemtokibart, an IL-22RA1-targeting monoclonal antibody, showing significant early and sustained efficacy in AD. New safety and efficacy data on delgocitinib from the DELTA TEEN trial, which looked at the performance of the cream in adolescent patients with CHE. LEO will also present pooled safety data from five delgocitinib trials in adults at the conference.
“Our pipeline also includes therapies for rare and less common skin diseases, underscoring our responsibility as a global leader to drive meaningful innovation for all patients,” Jacob P. Thyssen, MD, PhD, Chief Scientific Officer at LEO Pharma, said in a news release. “The breadth of our program—covering multiple disease areas from atopic dermatitis and chronic hand eczema to psoriasis—reflects LEO Pharma’s commitment to innovation across a wide portfolio."
Christophe Bourdon, CEO of LEO Pharma, emphasized the company’s scale and commitment
“Five late-breakers—for the second year in a row—in addition to our highest ever number of abstracts makes this a record-breaking contribution...across disease areas, applications and global markets,” he added in the press release.
Source: LEO Pharma news release. September 15, 2025.